It is hard to describe the Arthritis Advisory Committee’s December 20 rejection of Hemispherx Biopharma Inc.‘s Ampligen for Chronic Fatigue Syndrome as in any way surprising.
After all, this is an application with a remarkable track record of rejection at the Food & Drug Administration. The long regulatory history includes a Treatment IND that has been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?